Taxpayers overpaid about $1.27 billion for the allergy drug EpiPen over a decade, far more than the $465 million the drug’s manufacturer previously reported.
Sen. Chuck Grassley, R-Iowa, said Medicaid gave EpiPen maker Mylan too much money from 2006 to 2016 because Mylan misclassified the allergy antidote. The Obama administration also failed to adequately fix the issue, he added.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.